Skip to main content

SR One — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

64
Companies
$6.7B
Total invested
$105.0M
Avg. check
16
Industries
Biotechnology 20Health Care 16Therapeutics 13Medical 10Biopharma 5Life Science 5+10 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 64
Crystalys Therapeutics
July 2026

Crystalys Therapeutics is a clinical-stage biopharmaceutical company that develops targeted therapies for gout and hyperuricemia.

Biopharma · San Diego$130.0M Series B
Draig Therapeutics
July 2026

Draig Therapeutics is a clinical-stage biopharmaceutical company that develops investigational therapies for neuropsychiatric disorders.

Biopharma · Cardiff$65.0M Series B
Spero Therapeutics
July 2026

Spero Therapeutics develops therapeutics for treatment of gram-negative infections.

Biotechnology · Cambridge$105.0M Post-IPO Debt
Fore Biotherapeutics
July 2026

Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.

Biotechnology · Philadelphia$67.4M Series D
VeraDermics
April 2026

VeraDermics is a dermatology company that creates novel drug delivery mechanisms for a pain-free cure for skin conditions.

Health Care · New Haven$384.4M Post-IPO Equity
Immutrin
March 2026

Immutrin is a biotech developing next‑generation antibody therapies to clear amyloid deposits and reverse amyloidosis.

Biotechnology · Cambridge$87.1M Series A
AirNexis Therapeutics
January 2026

AirNexis Therapeutics develops clinical-stage therapies for chronic obstructive pulmonary disease and other pulmonary conditions.

Biotechnology · Palo Alto$200.0M Series A
Poplar Therapeutics
January 2026

Poplar Therapeutics anti-IgE therapy treats atopic diseases such as food allergy, allergic asthma, and atopic dermatitis.

Health Care · Cambridge$50.0M Series A
Addition Therapeutics
December 2025

Addition Therapeutics develops RNA-only therapeutics using PRINT technology for genetic medicine.

Biotechnology · South San Francisco$100.0M Series A
MISSION Therapeutics
October 2025

MISSION Therapeutics develops therapies that enhance the removal of dysfunctional mitochondria to combat serious diseases.

Biotechnology · Cambridge$13.3M Venture - Series Unknown
ARS Pharmaceuticals
September 2025

ARS Pharmaceuticals is a stealth pharmaceutical company that specializes in developing anti allergy drugs.

Biopharma · San Diego$100.0M Post-IPO Debt
Avenzo Therapeutics
September 2025

Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.

Biotechnology · San Diego$60.0M Series B
Akamis Bio
December 2024

Akamis Bio is a clinical-stage oncology company.

Biotechnology · Abingdon$60.0M Series A
Antag Therapeutics
December 2024

Antag Therapeutics provides therapeutic peptides for the treatment of dietary-related metabolic diseases.

Biotechnology · Copenhagen$84.1M Series A
Nomic
September 2024

Nomic develops a proteomic technology platform to understand, detect, and treat diseases with DNA nanotechnology.

Biotechnology · Montréal$42.0M Series B
Elektrofi
August 2024

Elektrofi is a preclinical-stage company dedicated to redefining the standard of drug delivery by transforming the patient experience.

Alternative Medicine · Boston$112.3M Series C
Renalys Pharma
July 2024

Renalys Pharma is a clinical-stage biopharmaceutical company developing therapeutics for renal disease in Asian patients.

Biopharma · Tokyo$38.5M Series A
Asceneuron
July 2024

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease.

Biotechnology · Lausanne$100.0M Series C
Effector Therapeutics
January 2024

Effector Therapeutics is an early-stage company focused on the discovery and development of small molecule cancer therapeutics.

Biotechnology · San Diego$15.0M Post-IPO Equity
Arcellx
November 2023

Arcellx develops engineered cell-based immunotherapies for the treatment of cancer and other serious diseases.

Biopharma · Redwood City$200.0M Post-IPO Equity
Morphic Therapeutic
May 2023

Morphic Therapeutic is a biotechnology company that develops oral integrin therapies to treat serious chronic diseases.

Biotechnology · Waltham$276.0M Post-IPO Equity
Pulmocide
December 2022

Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.

Biotechnology · London$52.0M Series C
MiroBio
June 2022

MiroBio is Harnessing the natural control mechanisms of the immune system.

Biotechnology · Oxford$97.0M Series B
Ancora Biotech
June 2022

Ancora Biotech is a privately held company supporting the clinical development of three multi-specific antibodies.

Biotechnology · Palo Alto$60.0M Series A

Where SR One invests

Biotechnology20
Health Care16
Therapeutics13
Medical10
Biopharma5
Life Science5

About SR One's portfolio

How many companies has SR One invested in?▸

SR One has invested in 64 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does SR One invest in?▸

SR One's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Biopharma. The firm invests across 16 different industry categories.

What is SR One's largest investment?▸

Among tracked funding rounds, VeraDermics received $384.4M in a Post-IPO Equity round. SR One's total known invested capital is $6.7B.

What is the average investment size for SR One?▸

SR One's average investment size is $105.0M across its portfolio of 64 companies.

What are SR One's most recent investments?▸

Recent SR One portfolio additions include Crystalys Therapeutics, Draig Therapeutics, Spero Therapeutics, Fore Biotherapeutics, VeraDermics. These companies were founded in 2020 or later.

Reach the founders behind these 64 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →